AilseBio

Executive Summary

AilseBio is a London-based private biotechnology company founded in 2021, pioneering a new class of immunotherapies through its proprietary TiNADiscovery platform. The platform generates Therapy Induced Novel Antigens (TiNAs), which are unique antigens presented on tumor cells in response to therapeutic intervention. Unlike conventional neoantigens, TiNAs are induced by treatment itself, potentially expanding the targetable antigen landscape and overcoming tumor heterogeneity. AilseBio's approach represents a novel frontier in immunotherapy, aiming to create more effective and durable anti-tumor responses. As a preclinical-stage company, AilseBio has not yet disclosed specific pipeline candidates or clinical trials, but its platform technology has garnered interest for its potential to address current limitations in cancer vaccine and cell therapy development. The company operates in the rapidly evolving field of immunotherapy, where innovative antigen discovery platforms are highly sought after by larger pharmaceutical partners.

Upcoming Catalysts (preview)

• Q2 2026Seed Funding or Series A Round Closing70% success
• TBDPreclinical Proof-of-Concept Data Release50% success
• 2026Strategic Partnership with Pharma for TiNADiscovery Platform40% success